KR900701834A - 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법 - Google Patents

사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법

Info

Publication number
KR900701834A
KR900701834A KR1019900700487A KR900700487A KR900701834A KR 900701834 A KR900701834 A KR 900701834A KR 1019900700487 A KR1019900700487 A KR 1019900700487A KR 900700487 A KR900700487 A KR 900700487A KR 900701834 A KR900701834 A KR 900701834A
Authority
KR
South Korea
Prior art keywords
neutrophil chemotactic
human
chemotactic factor
human neutrophil
administering
Prior art date
Application number
KR1019900700487A
Other languages
English (en)
Inventor
고우지 마쯔시마
라르센 크리스챤
오펜하임 죠오스트
야스노부 조무라
Original Assignee
원본미기재
유나이티드 스테이츠 가버먼트, 애즈 리프티젠티드 바이 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈
다이닛뽄 파마슈티칼 컴패니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 유나이티드 스테이츠 가버먼트, 애즈 리프티젠티드 바이 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈, 다이닛뽄 파마슈티칼 컴패니 리미티드 filed Critical 원본미기재
Publication of KR900701834A publication Critical patent/KR900701834A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5421—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

내용 없음

Description

사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한, 면역결핍상태에 의해 유발된 질병의 치료방법.
  2. 제1항에 있어서, 사람 호중구 화학주성 인자가 다음식으로 표시되는 아미노산 배열로 이루어지는 폴리펩티드인 것을 특징으로 하는 방법.
    SerAlaLysGluLeuArgCysGlnCysIleLysThr
    TyrSerLysProPheHisProLysPheIleLysGlu
    LeuArgVa1IleGluSerGlyProHisCysAlsAsn
    ThrGluI1eIleValLysLeuSerAspGlyArgGlu
    LeuGysLeuAspProLysGluAsnTrpValGlnArg
    ValvalGluLysPheLeuLysArgAlaGluAsnSer
  3. 제2항에 있어서, 사람 호증구 화학주성 인자 폴리펩티드가 재조합 DNA 기법에 의하여 미생물에서 생산되는 폴리펩티드인 것을 특징으로 하는 방법.
  4. 다음식으로 표시되는 아미노산 배열로 이루어지는 사람 호중구 화학주성 인자 폴리펩티드의 유효량을 투여하는 것에 의한, 면역 결핍 상태 또는 악성 종량의 치료방법.
    SerAlaLysGluLeuArgCysGlnCysIleLysThr
    TyrSerLysProPheHisProLysPheIleLysGlu
    LeuArgVa1IleGluSerGlyProHisCysAlsAsn
    ThrGluI1eIleValLysLeuSerAspGlyArgGlu
    LeuGysLeuAspProLysGluAsnTrpValGlnArg
    ValvalGluLysPheLeuLysArgAlaGluAsnSer
  5. 사람 호중구 화학주성 인자를 사람에 투여하는 것에 의한 T림프구의 활성화 방법.
  6. 사람 호중구 화학주성 인자 폴리펩티드를 포함하는 T림프구 활성 화제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019900700487A 1988-07-07 1989-07-07 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법 KR900701834A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21641888A 1988-07-07 1988-07-07
US216,418 1988-07-07
PCT/US1989/002904 WO1990000563A1 (en) 1988-07-07 1989-07-07 A method of treating diseases caused by immunodeficiency states by administering human neutrophil chemotactic factor to human

Publications (1)

Publication Number Publication Date
KR900701834A true KR900701834A (ko) 1990-12-04

Family

ID=22806992

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900700487A KR900701834A (ko) 1988-07-07 1989-07-07 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법

Country Status (4)

Country Link
EP (1) EP0423193A4 (ko)
JP (1) JPH03505730A (ko)
KR (1) KR900701834A (ko)
WO (1) WO1990000563A1 (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789539A (en) * 1994-10-26 1998-08-04 Repligen Corporation Chemokine-like proteins and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3890998B4 (de) * 1987-11-19 2008-01-03 Novartis Ag Neutrophilenaktivierungsfaktor, Verfahren zu seiner Herstellung und ihn enthaltende pharmazeutische Zusammensetzung

Also Published As

Publication number Publication date
WO1990000563A1 (en) 1990-01-25
JPH03505730A (ja) 1991-12-12
EP0423193A4 (en) 1991-10-16
EP0423193A1 (en) 1991-04-24

Similar Documents

Publication Publication Date Title
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
KR880701288A (ko) M-csf의 제법
LU91087I2 (fr) Advate(Octocog alfa) soustotes ses formes protégées par le brevet de base.
MX166499B (es) Interferon recombinante inmune humano y composicion farmaceutica que lo incluye
IL96907A0 (en) Proteins produced by human lymphocytes,a dna sequence coding for said proteins and their pharmaceutical and biological application
DE68916537D1 (de) Herstellung eines insulinähnlichen, wachstümsfaktor bindenden proteins.
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
KR900013979A (ko) 사람 유두종비루스형 16의 e7 단백질상의 면역원성 영역
SE9002589L (sv) Neutrofil-aktiverande peptid-2
ATE85809T1 (de) Herstellung des menschlichen von-willebrandfaktors durch rekombinante dns.
DE3752158D1 (de) Molekulare Klonierung und Expression von menschlichem IL-3
ES2138973T3 (es) Muteinas de il-6 exentas de cisteina.
ES2081817T3 (es) Polipeptido con secuencias principales repetidas que se fijan en la celula.
AU567747B2 (en) Early detection of mammalian pregnancy
DE3775389D1 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
DE3881023D1 (de) Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten.
PT81345A (de) Neue zns-aktive peptide mit wirkung auf das cholinerge system
DE3063339D1 (en) Peptides with pharmacological activity and medicines containing them
KR900701834A (ko) 사람 호중구 화학주성 인자를 사람에게 투여하는 것에 의한 면역결핍 상태에 의해 유발된 질병의 치료방법
ES2080060T3 (es) Proteinas que tienen actividad de union a interferon-gamma.
ATE120209T1 (de) Isolierung von einkettigen proteinen mit fsh unter- drückender aktivität aus follikularflüssigkeit.
DE3584926D1 (de) Behandlung von oedemen mit hohem proteingehalt durch direktes aufbringen von benzopyronen.
KR870005645A (ko) 신규세포 생장조절 인자
ATE166068T1 (de) Vom endonukleaseprotein des menschlichen immunschwäche virus abgeleitete polypeptide
DE68917944T2 (de) O.R.I.-gehemmte Motorbrennstoffzusammensetzung, und einlagerungsbeständiges Konzentrat.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid